← Back to Investor Relations
In the Press
Quest Diagnostics to Offer Liver Cancer Blood Test
Why This Matters
Becker's ASC Review reaches 609,000 monthly visitors including ASC leaders, gastroenterologists, and health system decision-makers — the exact stakeholders who influence clinical adoption of new diagnostic technologies like HelioLiver.
Article Summary
Becker's ASC Review reports that Quest Diagnostics will offer HelioLiver, Helio Genomics' blood-based test designed for early detection of hepatocellular carcinoma, through its nationwide provider network starting April 2026. The article, which was subsequently syndicated by NewsBreak to 13.9 million readers, highlights the test's availability through Quest's established ordering and EHR systems.